World Health Organization (WHO) recommends the use of arthritis drugs Actemra from Roche and Kevzara from Sanofi for COVID-19 patients. Data from about 11,000 patients showed that both drugs were able to reduce the risk of death and the need for mechanical ventilation.
“We have updated our clinical care guidelines to reflect these latest developments,” said WHO Health Emergencies official Janet Diaz Channel News Asia, Wednesday (7/7/2021).
The data comes from WHO research conducted with King’s College London, the University of Bristol, University College London, and the Guy’s and St Thomas NHS Foundation Trust.
The study involved 10,930 patients who were given different treatments. A total of 6,449 people were given one of the inflammatory drugs, and another 4,481 received standard care or a placebo.
However, drug testing Actemra and Kevzara for COVID-19 patient this involves trial and error. This is because there are several failures that arise when companies try these drugs on different groups of patients.
However, the WHO also called for more to be done to increase access to these medicines. Especially for the lowest-income countries that are facing a spike in cases COVID-19 and exacerbated by inadequate vaccine stocks.
“These are the people that these drugs need to reach,” Diaz said.
Not long ago, Actemra also just received emergency use approval from the United States Food and Drug Administration (FDA).
Watch Videos”WHO Does Not Stop Issuing Corona Warning“
[Gambas:Video 20detik]
(star/kna)
– .
